VivoSim Labs (VIVS) Cash from Investing Activities (2010 - 2026)
VivoSim Labs (VIVS) posted quarterly Cash from Investing Activities of $94000.0 for Q1 2026, down 98.96% year-over-year from $9.0 million in Q1 2025, and down 98.96% quarter-over-quarter from $9.0 million in Q1 2025.
VivoSim Labs (VIVS) Cash from Investing Activities (2010 - 2026) Analysis & Trends
VivoSim Labs' Cash from Investing Activities history runs 16 years deep, the most recent figure standing at $94000.0 for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 98.96% year-over-year to $94000.0; the TTM figure through Mar 2026 stood at $94000.0 (down 98.96% YoY), while the FY2026 annual figure was $94000.0, down 98.96% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $94000.0, down from $9.0 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $10.0 million in Q4 2022, with the low at -$10.7 million in Q2 2022.
- The 5-year median for Cash from Investing Activities is $13000.0 (2024), against an average of $685846.2.
- The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities sank 5411.86% in 2022, then soared 69138.46% in 2025.
- VivoSim Labs' Cash from Investing Activities stood at $10.0 million in 2022, then tumbled by 99.73% to $27000.0 in 2023, then plunged by 85.19% to $4000.0 in 2024, then surged by 224925.0% to $9.0 million in 2025, then tumbled by 98.96% to $94000.0 in 2026.
- Business Quant data shows VIVS's Cash from Investing Activities at $94000.0 in Q1 2026, $9.0 million in Q1 2025, and $4000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | -23,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23,000.00 |
| Jun 30, 2026 | -23,000.00 |
| Mar 31, 2026 | 94,000.00 |
| Mar 31, 2026 | 94,000.00 |
| Mar 31, 2025 | 9.00 Mn |
| Mar 31, 2025 | 9.00 Mn |
| Dec 31, 2024 | 4,000.00 |
| Dec 31, 2024 | 4,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Dec 31, 2023 | 27,000.00 |
| Dec 31, 2023 | 27,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Jun 30, 2023 | 764,000.00 |
| Jun 30, 2023 | 764,000.00 |
| Mar 31, 2023 | -162,000.00 |
| Mar 31, 2023 | -162,000.00 |